Janux Therapeutics annual return on equity
2021
2022
2023
2024
2025
Janux Therapeutics Return on Equity (ROE) Growth & History (JANX)
Janux Therapeutics's return on equity was −11.48% for fiscal 2025.
View full Janux Therapeutics company overviewJanux Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −11.48% | −1.39 pp |
| 2024 | 2024-12-31 | −10.09% | +7.44 pp |
| 2023 | 2023-12-31 | −17.53% | +0.83 pp |
| 2022 | 2022-12-31 | −18.36% | +0.22 pp |
| 2021 | 2021-12-31 | −18.58% | — |
Janux Therapeutics quarterly return on equity
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −2.35% | +1.03 pp |
| Q1 2026 | 2026-03-31 | −2.57% | −0.26 pp |
| Q4 2025 | 2025-12-31 | −3.30% | −0.90 pp |
| Q3 2025 | 2025-09-30 | −2.47% | +1.80 pp |
| Q2 2025 | 2025-06-30 | −3.38% | −2.47 pp |
| Q1 2025 | 2025-03-31 | −2.31% | +0.64 pp |
| Q4 2024 | 2024-12-31 | −2.41% | +0.98 pp |
| Q3 2024 | 2024-09-30 | −4.27% | −0.70 pp |
| Q2 2024 | 2024-06-30 | −0.91% | +4.83 pp |
| Q1 2024 | 2024-03-31 | −2.95% | +2.57 pp |
| Q4 2023 | 2023-12-31 | −3.39% | +1.53 pp |
| Q3 2023 | 2023-09-30 | −3.57% | +1.38 pp |
| Q2 2023 | 2023-06-30 | −5.73% | −0.91 pp |
| Q1 2023 | 2023-03-31 | −5.52% | −1.81 pp |
| Q4 2022 | 2022-12-31 | −4.93% | −1.32 pp |
| Q3 2022 | 2022-09-30 | −4.94% | −2.12 pp |
| Q2 2022 | 2022-06-30 | −4.83% | −1.47 pp |
| Q1 2022 | 2022-03-31 | −3.71% | — |
| Q4 2021 | 2021-12-31 | −3.61% | — |
| Q3 2021 | 2021-09-30 | −2.83% | — |
| Q2 2021 | 2021-06-30 | −3.35% | — |
Janux Therapeutics return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Janux Therapeutics's return on equity increased from −18.58% to −11.48%, a change of +7.10 percentage points. The latest reported quarter, Q2 2026, shows −2.35%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Janux Therapeutics source filings ↗